Inhibikase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Option Activity Under 2011 Plan and 2020 Plan

The following is a summary of option activity under the 2011 Plan and the 2020 Plan:


	Number of Shares			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (In Years)
Outstanding at December 31, 2019		3,369,144		$	1.75		7.78
Granted		227,300			10.00		6.98
Exercised		—			—		—
Forfeited		—			—		—
Cancelled		—			—		—
Outstanding at December 31, 2020		3,596,444			2.27		7.73
Granted		215,898			3.88		6.40
Exercised		(112,268	)		0.70		—
Forfeited		(40,708	)		0.38		—
Cancelled		—			—		—
Outstanding at December 31, 2021		3,659,366			2.43		6.99
Exercisable at December 31, 2021		3,378,761			2.13		7.05

Schedule of Estimated Assumptions of Weighted-Average Fair Values of Options Granted

The weighted-average fair values of options granted in the years ended December 31, 2021 and 2020 were $2.24 and $6.45, per share, respectively, and were calculated using the following estimated assumptions:


	Year ended December 31,
	2021			2020
Weighted-average risk-free interest rate		0.59	%		0.32	%
Expected dividend yield		0.00	%		0.00	%
Expected volatility		82.22	%		87.63	%
Expected terms	3.97 years			4.44 years

Summary of Stock-Based Compensation Expense for Stock Options Granted to Employees and Non-Employees

The following table summarizes the stock-based compensation expense for stock options granted to employees and non-employees:


	Year ended December 31,
	2021		2020
Research and development	$	665,834	$	261,492
Selling, general and administrative		866,042		312,203
Total stock-based compensation expense	$	1,531,876	$	573,695